Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D0FX
|
|||
| Former ID |
DNC013506
|
|||
| Drug Name |
1-(1,3,4-oxadiazol-2-yl)octadec-9-en-1-one
|
|||
| Synonyms |
CHEMBL178791; 1-(1,3,4-oxadiazol-2-yl)octadec-9-en-1-one; BDBM50161529; 1-[1,3,4]Oxadiazol-2-yl-octadec-9-en-1-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H34N2O2
|
|||
| Canonical SMILES |
CCCCCCCCC=CCCCCCCCC(=O)C1=NN=CO1
|
|||
| InChI |
1S/C20H34N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-19(23)20-22-21-18-24-20/h9-10,18H,2-8,11-17H2,1H3/b10-9-
|
|||
| InChIKey |
JPZIIIRVMJASPM-KTKRTIGZSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fatty acid amide hydrolase (FAAH) | Target Info | Inhibitor | [1] |
| BioCyc | Anandamide degradation | |||
| KEGG Pathway | Retrograde endocannabinoid signaling | |||
| Panther Pathway | Anandamide degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.